Chemistry:Emicizumab

From HandWiki

Emicizumab, sold under the brand name Hemlibra, is a humanized bispecific monoclonal antibody for the treatment of haemophilia A, developed by Genentech and Chugai (both organizations are subsidiaries of Hoffmann-La Roche).[1] Emicizumab is a bispecific factor IXa- and factor X-directed antibody.[2][3][4]

Emicizumab was first approved by the U.S. Food and Drug Administration (FDA) in November 2017 for routine prophylaxis in patients with hemophilia A who have developed factor VIII inhibitors.[5][6] In October 2018, the FDA expanded approval, under the breakthrough therapy designation , to include all patients with hemophilia A, regardless of inhibitor status.[7][8] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[9] It is on the World Health Organization's List of Essential Medicines.[10]

Medical uses

Emicizumab is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in people with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.[2]

Available forms

Emicizumab is administered as a subcutaneous injection with flexible dosing options.[11] The drug can be administered once weekly, every two weeks, or every four weeks, providing patients and healthcare providers with dosing flexibility based on individual needs and preferences.[11]

The long elimination half-life of approximately 28-32 days supports the extended dosing intervals, making it more convenient compared to traditional factor VIII replacement therapy, which typically requires more frequent administration.[12]

Adverse effects

The most common adverse reactions (incidence ≥10%) are injection site reactions, headache, and arthralgia.[2]

Pharmacology

Pharmacokinetics

The long elimination half-life of approximately 28-32 days supports the extended dosing intervals, making it more convenient compared to traditional factor VIII replacement therapy, which typically requires more frequent administration.[12]

Mechanism of action

Emicizumab is a bispecific antibody that simultaneously binds to activated coagulation factor IX (FIXa) and factor X (FX), bringing these coagulation factors into spatial proximity to facilitate the activation of factor X.[12] This mechanism mimics the natural cofactor function of activated factor VIII (FVIIIa) in the coagulation cascade, effectively replacing the missing or deficient clotting factor in patients with hemophilia A.[13][1][14]

Unlike traditional factor VIII replacement therapy, emicizumab functions independently of factor VIII levels and is not neutralized by factor VIII inhibitors.[3] This unique mechanism makes it particularly valuable for patients who have developed inhibitory antibodies against factor VIII, a complication that affects approximately 20-30% of patients with severe hemophilia A.[15]

Research

A Phase I clinical trial found that it was well tolerated by healthy subjects.[16]

Studies indicate that emicizumab is a better therapy compared to the previous generations, due to subcutaneous administration and fewer injections, which reduces injection site reactions and makes therapy less troublesome.[17]

HAVEN clinical trial program

Emicizumab was evaluated in one of the largest pivotal clinical trial programs in hemophilia A, comprising four pivotal Phase III studies known as the HAVEN trials.[18]

HAVEN 1 study

HAVEN 1 was a randomized, multicenter, open-label Phase III trial that included 109 male patients (ages 12-75 years) with severe hemophilia A and factor VIII inhibitors.[19] The study demonstrated that emicizumab prophylaxis significantly reduced bleeding episodes compared to no prophylaxis in patients with inhibitors.[20][21][22]

HAVEN 3 study

HAVEN 3 evaluated emicizumab in patients with severe hemophilia A without factor VIII inhibitors. The trial demonstrated that subcutaneous emicizumab prophylaxis, administered either once weekly or every two weeks, resulted in bleeding rates that were significantly lower by more than 95% compared to no prophylaxis.[4] More than 55% of participants in each randomized emicizumab regimen experienced no treated bleeds during the study period.[4][23]

Additional HAVEN studies

The clinical program also included HAVEN 2 (pediatric patients with inhibitors) and HAVEN 4 (patients switching from bypassing agent prophylaxis), further establishing the efficacy and safety profile of emicizumab across different patient populations.[24]

Regulatory approvals

Emicizumab received its first regulatory approval from the FDA on November 16, 2017, under the brand name Hemlibra for routine prophylaxis in adult and pediatric patients with hemophilia A who have developed factor VIII inhibitors.[5] This approval was based on results from the HAVEN 1 and HAVEN 2 clinical trials.[25][26]

On October 4, 2018, the FDA expanded the approval under the Breakthrough Therapy designation to include all adult and pediatric patients (newborn and older) with hemophilia A, regardless of inhibitor status.[7] This expanded approval was based on data from the HAVEN 3 and HAVEN 4 studies.[18]

Emicizumab has since received regulatory approvals in numerous countries worldwide, including approval by the European Medicines Agency (EMA) and other international regulatory authorities.[24]

See also

References

  1. ↑ 1.0 1.1 "Neue Wirkstoffe - Emicizumab" (in German). Österreichische Apothekerzeitung (14/2016). 4 July 2016. 
  2. ↑ 2.0 2.1 2.2 Cite error: Invalid <ref> tag; no text was provided for refs named Hemlibra FDA label
  3. ↑ 3.0 3.1 "Emicizumab". StatPearls. StatPearls Publishing. July 4, 2023. https://www.ncbi.nlm.nih.gov/books/NBK559180/. 
  4. ↑ 4.0 4.1 4.2 "Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors". New England Journal of Medicine 379 (9): 811–822. 2018. doi:10.1056/NEJMoa1803550. PMID 29365805. 
  5. ↑ 5.0 5.1 "FDA approves emicizumab-kxwh for prevention and reduction of bleeding in patients with hemophilia A with factor VIII inhibitors". November 16, 2017. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-emicizumab-kxwh-prevention-and-reduction-bleeding-patients-hemophilia-factor-viii. 
  6. ↑ "Roche hemophilia drug wins FDA nod, with a warning". Reuters. 17 November 2017. https://www.reuters.com/article/us-roche-hemlibra/roche-hemophilia-drug-wins-fda-nod-with-a-warning-idUSKBN1DG2C4. 
  7. ↑ 7.0 7.1 "FDA approves emicizumab-kxwh for hemophilia A with or without factor VIII inhibitors". October 4, 2018. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-emicizumab-kxwh-hemophilia-or-without-factor-viii-inhibitors. 
  8. ↑ "FDA Grants Roche Breakthrough Therapy Designation on Hemophilia Drug". BioPharm International (UBM). 19 April 2018. http://www.biopharminternational.com/fda-grants-roche-breakthrough-therapy-designation-hemophilia-drug. 
  9. ↑ (PDF) New Drug Therapy Approvals 2017 (Report). January 2018. https://www.fda.gov/media/110526/download. Retrieved 16 September 2020. 
  10. ↑ The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list. Geneva: World Health Organization. 2025. 
  11. ↑ 11.0 11.1 "Clinical pharmacology of emicizumab for the treatment of hemophilia A". Expert Review of Clinical Pharmacology 16 (9): 775–790. 2023. doi:10.1080/17512433.2023.2243213. PMID 37529848. 
  12. ↑ 12.0 12.1 12.2 "Emicizumab: Uses, Interactions, Mechanism of Action". https://go.drugbank.com/drugs/DB13923. 
  13. ↑ "Traction apophysitis of the knee: A case report". Radiology Case Reports 14 (1): 18–21. January 2019. doi:10.1016/j.radcr.2018.09.012. PMID 30305859. 
  14. ↑ "Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A". The New England Journal of Medicine 374 (21): 2044–2053. May 2016. doi:10.1056/NEJMoa1511769. PMID 27223146. 
  15. ↑ "Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A". Thrombosis and Haemostasis 120 (10): 1357–1370. October 2020. doi:10.1055/s-0040-1714279. PMID 32717759. 
  16. ↑ "A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects". Blood 127 (13): 1633–1641. March 2016. doi:10.1182/blood-2015-06-650226. PMID 26626991. 
  17. ↑ "Emicizumab as a Promising Form of Therapy for Type A Hemophilia - A Review of Current Knowledge from Clinical Trials". Current Protein & Peptide Science 25 (9): 719–737. May 2024. doi:10.2174/0113892037294674240509094418. PMID 38797909. 
  18. ↑ 18.0 18.1 "FDA Approves Genentech's Hemlibra (emicizumab-kxwh) for People With Hemophilia A Without Factor VIII Inhibitors". October 4, 2018. https://www.gene.com/media/press-releases/14749/2018-10-04/fda-approves-genentechs-hemlibra-emicizu. 
  19. ↑ Emicizumab-kxwh Approved by FDA for Patients With Hemophilia A and Inhibitors. December 30, 2021. https://ashpublications.org/ashclinicalnews/news/3600/Emicizumab-kxwh-Approved-by-FDA-for-Patients-With. Retrieved 2025-08-21. 
  20. ↑ "Emicizumab Prophylaxis in Hemophilia A with Inhibitors". The New England Journal of Medicine 377 (9): 809–818. August 2017. doi:10.1056/NEJMoa1703068. PMID 28691557. 
  21. ↑ Hoffmann-La Roche (2021-05-26). A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Patients With Inhibitors (Report). clinicaltrials.gov. https://clinicaltrials.gov/study/NCT02622321. 
  22. ↑ Hospices Civils de Lyon (2025-01-09). EVALUATION of the OVERALL HAEMOSTATIC CAPACITY of MIM8 with GLOBAL HAEMOSTASIS ASSAYS and FIBRIN CLOT ULTRASTRUCTURE (Report). clinicaltrials.gov. https://clinicaltrials.gov/study/NCT06212505. 
  23. ↑ Hoffmann-La Roche (2022-10-19). A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Patients Without Inhibitors (Report). clinicaltrials.gov. https://clinicaltrials.gov/study/NCT02847637. 
  24. ↑ 24.0 24.1 "Loss of MLKL ameliorates liver fibrosis by inhibiting hepatocyte necroptosis and hepatic stellate cell activation". Theranostics 12 (11): 5220–5236. 2022. doi:10.1111/hae.14597. PMID 35836819. 
  25. ↑ "Variation in the proportion of the segregating genome shared between full-sibling cattle and sheep". Genetics, Selection, Evolution 55 (1): 27. April 2023. doi:10.3324/haematol.2023.283237. PMID 37072693. 
  26. ↑ Hoffmann-La Roche (2021-05-07). A Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Administration of Emicizumab in Hemophilia A Pediatric Patients With Inhibitors (Report). clinicaltrials.gov. https://clinicaltrials.gov/study/NCT02795767. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Emicizumab&oldid=4016569"